Upcoming Webinar (Nov 17 @4p ET) – Do AI Scribes Help or Harm Older Adults? Randomized Trial Evidence, Open Questions and an Introduction to APEX-ADRD
Registration: https://tinyurl.com/MassAITC-November2026-webinar Abstract: Ambient generative AI scribes are spreading across U.S. health systems faster than evidence about their effects can be generated. A recent meta-analysis found that only 0.4% of studies of AI in medicine were real-world randomized trials, and the stakes of that gap are highest for older adults, who carry the greatest burdens of multimorbidity, polypharmacy, and cognitive impairment and are the most exposed to any change in how clinicians diagnose, prescribe, and communicate. This webinar opens with a brief introduction to APEX-ADRD (Accelerating Platforms for Evaluating and eXecuting AI Lifecycles in Alzheimer's Disease and Related Dementias), an NIA-funded AI and Technology Collaboratory based at UCLA that serves investigators and technology developers nationwide and supports pilot projects across the full AI lifecycle, from AI-ready data and model development to pragmatic trials and post-deployment…
